CVRx Inc. (CVRX) is a Medical/Dental Instruments company listed on NASDAQ. In the last 30 days Quantisnow tracked 8 wire items for CVRX, including 3 SEC filings, 2 earnings updates and 2 analyst ratings. The most recent was published Nov 6, 2026.
Financial highlights
Full financials- Revenue, TTM
- $60.33M
- Revenue growth
- +7.8%
- Net income, TTM
- -$53.26M
- Net margin
- -88.3%
- Free cash flow, TTM
- -$42.05M
- Cash
- $58.75M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks39+300%
2026-05-172026-11-08
Mix1790d
- SEC Filings5(29%)
- Other4(24%)
- Leadership2(12%)
- Insider2(12%)
- Earnings2(12%)
- Analyst2(12%)
Activity · 52 weeks8045 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- ANALYSTCVRx, Inc. downgraded by Canaccord Genuity with a new price targetCanaccord Genuity downgraded CVRx, Inc. from Buy to Hold and set a new price target of $2.00
- ANALYSTCVRx, Inc. downgraded by William BlairWilliam Blair downgraded CVRx, Inc. from Outperform to Mkt Perform
- SECSEC Form S-8 filed by CVRx Inc.S-8 - CVRx, Inc. (0001235912) (Filer)
- SECSEC Form 10-Q filed by CVRx Inc.10-Q - CVRx, Inc. (0001235912) (Filer)
- SECCVRx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - CVRx, Inc. (0001235912) (Filer)
- PRCVRx Reports Third Quarter 2026 Financial and Operating ResultsMINNEAPOLIS, Nov. 05, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the third quarter of 2026. Recent Highlights Total revenue for the third quarter of 2026 was $13.8 millionU.S. revenue for the third quarter of 2026 was $13.0 millionActive implanting centers in the U.S. increased to 262 as of September 30, 2026, as compared to 250 as of September 30, 2025A second major Medicare Advantage provider has issued a coverage policy for Barostim, e
- PRCVRx to Participate in Upcoming Investor ConferencesMINNEAPOLIS, Nov. 02, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will participate in the following investor conferences: Canaccord Genuity Medtech, Diagnostics & Digital Health Services Forum in New York on Wednesday, Nov. 11, 2026. The fireside chat is scheduled at 8:00 a.m. (ET) the same day via webcast.Jefferies Global Healthcare Conference in London on Thursday, Nov. 19, 2026. The Company's presentation will begin at 1:00 p.m. (GMT) / 9:00 a.m. (ET) th
- PRCVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026MINNEAPOLIS, Oct. 22, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release third quarter 2026 financial and operating results after market close on Thursday, Nov. 5, 2026. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company’s website at ir.cvrx.com. To listen to the conference call on your telephone,
- SECCVRx Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - CVRx, Inc. (0001235912) (Filer)
- PRCVRx Appoints John Landry as Chief Financial OfficerMINNEAPOLIS, Sept. 21, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that John Landry has been appointed Chief Financial Officer, succeeding Jared Oasheim, whose resignation was previously announced. Mr. Landry will join the Company on October 12, 2026, and assume the CFO role on the day after the Company files its Form 10-Q for the quarter ending September 30, 2026. Mr. Oasheim will remain with the Company for a transition period consistent with his previously disclosed transition
- PRCVRx Responds to Letter from Pointillist Family OfficeMINNEAPOLIS, Aug. 25, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today issued the following statement in response to the public letter to CVRx’s Board of Directors from Jorey Chernett at Pointillist Family Office, dated August 24, 2026: The Board of Directors and leadership team are committed to acting in the best interests of all CVRx shareholders and regularly evaluate a full range of options to maximize value for all shareholders. The Board values all shareholder input and appreciates the open
- PRJorey Chernett, Owner of More than 5.5% of Outstanding Shares of CVRx, Calls on Board to Begin Immediate Process to Pursue Sale of the Company to a Strategic AcquirerDelivers Letter to the CVRx Board Highlighting Significant Value Proposition of Barostim to a Large Medical Device Company with Established Infrastructure to Capitalize on the Product's Market PositionBLOOMFIELD HILLS, Mich., Aug. 24, 2026 /PRNewswire/ -- Jorey Chernett, Founder of Pointillist Family Office and beneficial owner of more than 5.5% of the outstanding shares of CVRx, Inc. ("CVRx" or the "Company") (NASDAQ:CVRX), today delivered a letter to the CVRx Board of Directors (the "Board"), urging it to launch an immediate and formal process to sell the Company to a strategic acquirer. In the letter, Mr. Chernett outlines why CVRx, through its Barostim pro
- PRCVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim TherapyMINNEAPOLIS, Aug. 24, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Devoted Health has issued a Medicare Advantage coverage policy for Barostim therapy, effective July 17, 2026. Devoted Health, a national health insurance company with the eighth largest Medicare Advantage enrollment in the U.S., provides coverage to approximately 466,000 Medicare Advantage members across 29 states. The new policy covers Barostim for patients meeting its current FDA-approved indication as well as
- INSIDERCHIEF OPERATING OFFICER Binkowski Brent bought $76,432 worth of shares (26,223 units at $2.91), increasing direct ownership by 87% to 56,514 units (SEC Form 4)4 - CVRx, Inc. (0001235912) (Issuer)
- INSIDERCHIEF OPERATING OFFICER Binkowski Brent sold $3,338 worth of shares (1,309 units at $2.55), decreasing direct ownership by 4% to 30,291 units (SEC Form 4) (tax liability)4 - CVRx, Inc. (0001235912) (Issuer)
- SECCVRx Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - CVRx, Inc. (0001235912) (Filer)
- PRCVRx Announces Sales Leadership TransitionMINNEAPOLIS, Aug. 11, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that Robert John, Chief Revenue Officer, will depart the company, and that Paul Verrastro will assume the role of Interim Head of Sales, effective immediately. In his new role, Mr. Verrastro will lead CVRx's sales organization while the company conducts a search for a permanent successor. Mr. Verrastro brings more than 30 years of medical device sales and marketing experience to the role. He has been with CVRx for o
- ANALYSTCVRx, Inc. downgraded by Craig Hallum with a new price targetCraig Hallum downgraded CVRx, Inc. from Buy to Hold and set a new price target of $4.00
- ANALYSTCVRx, Inc. downgraded by Lake Street with a new price targetLake Street downgraded CVRx, Inc. from Buy to Hold and set a new price target of $3.50
- ANALYSTCVRx, Inc. downgraded by Piper Sandler with a new price targetPiper Sandler downgraded CVRx, Inc. from Overweight to Neutral and set a new price target of $4.00
- SECSEC Form 10-Q filed by CVRx Inc.10-Q - CVRx, Inc. (0001235912) (Filer)
- SECCVRx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - CVRx, Inc. (0001235912) (Filer)
- PRCVRx Reports Second Quarter 2026 Financial and Operating ResultsMINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the second quarter of 2026. Recent Highlights Total revenue for the second quarter of 2026 was $15.7 million, an increase of approximately 16% over the prior year quarterU.S. revenue for the second quarter of 2026 was $14.8 million, an increase of 21% over the prior year quarterActive implanting centers in the U.S. grew to 258 as of June 30, 2026, as compared to 240 as of June
- PRCVRx to Present at Canaccord Genuity's 46th Annual Growth ConferenceMINNEAPOLIS, July 28, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that the management team will present at Canaccord Genuity's 46th Annual Growth Conference in Boston on Tuesday, August 11, 2026. The Company's presentation will begin at 1:00 p.m. (ET). A live webcast of the event can be found at ir.cvrx.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time. About CVRx, Inc. CVRx is a com
- PRCVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026MINNEAPOLIS, July 23, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release second quarter 2026 financial and operating results after market close on Thursday, August 6, 2026. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day.A live webcast of the investor conference call will be available online at the investor relations page of the Company’s website at ir.cvrx.com. To listen to the conference call on your telephone,
CVRX FAQ
10 questionsWhat is the latest news on CVRX?
In the last 30 days Quantisnow tracked 8 wire items for CVRX: 3 SEC filings, 2 earnings updates, 2 analyst ratings and 1 press release or news item. The most recent was published on November 6, 2026.What is CVRX revenue?
CVRx Inc. (CVRX) reported $60.33M of revenue for the twelve months ended Sep 30, 2026. That is up 7.8% from the year before. Revenue for fiscal 2025 was $56.65M.Is CVRX profitable?
No. CVRx Inc. reported a net loss of $53.26M for the twelve months ended Sep 30, 2026.How much cash and debt does CVRX have?
CVRx Inc. reported $58.75M in cash and cash equivalents and $58.66M of debt on its most recent balance sheet in SEC filings.Where does CVRX stock trade?
CVRx Inc. (CVRX) is listed on NASDAQ.What sector and industry is CVRX in?
CVRx Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did CVRx Inc. go public?
CVRx Inc. (CVRX) completed its IPO in 2021.What are analysts saying about CVRX?
Across the last 8 analyst actions on CVRx Inc., there was 1 upgrade and 6 downgrades. The most recent action was from Canaccord Genuity: Hold with a $2.00 price target on 2026-11-06.What companies are similar to CVRX?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare CVRX side-by-side with any of them on Quantisnow.How can I track CVRX on Quantisnow?
Quantisnow aggregates CVRx Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CVRX to receive live email and push alerts on every new disclosure.